Warhound Launch: $200 Million Funded to Build Genetically Enhanced Military Dogs

Colossal Biosciences and Anduril have officially unveiled Warhound, a new venture designed to genetically engineer dogs for military and law enforcement use. The company emerged from stealth mode on Thursday with a significant $200 million funding round. Investors backing the project include Sequoia, 8VC, Corner Ventures, and In-Q-Tel, a firm supported by U.S. intelligence agencies. This investment values the startup at $1.2 billion as it prepares to tackle a critical gap in national defense resources.

The impetus for the venture stems from a growing concern about the supply of working dogs. Currently, over 80% of the U.S. military’s working dogs are sourced from Europe, and fewer than half of those imported animals are fit for service. This reliance on foreign nations has created a dwindling supply of essential canine partners. Ben Lamm of Colossal Biosciences and Palmer Luckey of Anduril met at a conference about a year ago and began collaborating to address this issue. Lamm researched breeding practices and identified inherited health problems, such as poor eyesight and hip dysplasia, that often prevent dogs from completing training.

Warhound’s approach combines biological engineering with technological hardware. The team has collected cell lines from top-performing breeds, including Belgian Malinois and German Shepherds, and stored them in a biobank. They plan to edit these genes to enhance traits like speed, agility, and olfactory sensitivity while removing genes associated with common health issues. Anduril will provide the necessary gear, such as protective vests and goggles equipped with data sensors. These tools will offer handlers real-time situational awareness, effectively placing enhancements on the dog rather than inside it to improve safety and performance.

The operational timeline is ambitious. The first batch of dogs is expected to be cloned and incubated soon, with births anticipated early next year. The goal is for these animals to begin service within two years. Viagen, another company owned by Colossal, will handle the cloning process using technology that boasts a high success rate. Lamm noted that the company has briefed various government groups on its plans, though specific pricing for the dogs has not yet been determined. The primary customers will include first responders, the Department of Defense, and police forces.

Civilian safety and animal welfare are central to the company’s strategy. Lamm stated that each dog will undergo standard military training and be managed by its purchasing agency. To ensure ethical treatment, Warhound is working under the guidance of the American Humane Society. The organization will help certify the training program and potentially provide homes for retired dogs through its reunification program. The American Humane Society welcomed the collaboration, expressing hope that the partnership ensures the animals are treated humanely.

While Colossal is known for its de-extinction efforts, such as attempts to revive the dodo and mammoth, this project marks a distinct application of its technology. Lamm emphasized that the goal is to create a new type of dog that is safer, healthier, and better suited for demanding missions. By integrating genetic enhancements with Anduril’s hardware, the company aims to protect both the dogs and their human handlers in the line of duty.